Geode Capital Management
NNNN

Geode Capital Management’s Anbio Biotechnology NNNN Stock Holding History

Geode Capital Management’s Portfolio NNNN Stock Details NNNN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$662K Hold
25,763
– – ﹤0.01% 3484
2025
Q4 		$775K Hold
25,763
– – ﹤0.01% 3452
2025
Q3 		$960K Buy
25,763
+8,633
+50% +$388K ﹤0.01% 3393
2025
Q2 		$542K Buy
17,130
+70
+0.4% +$670 ﹤0.01% 3531
2025
Q1 		$127K Buy
+17,060
New +$117K ﹤0.01% 3966

Other funds holding NNNN

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFS
Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Geode Capital Management's NNNN Position: Q1 2026 in Review

Geode Capital Management held its Anbio Biotechnology (NNNN) position steady in Q1 2026 at 25,763 shares worth $662K. The position accounts for ﹤0.01% of the portfolio, ranked #3484.

Geode Capital Management first reported a position in NNNN in Q1 2025 and has held it in 5 quarters since. The position peaked at $960K in Q3 2025. 8 funds tracked by Wall St. Rank hold NNNN as of Q1 2026.

  • Geode Capital Management held 25,763 shares of Anbio Biotechnology worth $662K as of Q1 2026.
  • Geode Capital Management left its Anbio Biotechnology share count unchanged in Q1 2026.
  • Anbio Biotechnology made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3484 holding.
  • Geode Capital Management first reported a position in Anbio Biotechnology in Q1 2025 and has held it in 5 quarters since.
  • Geode Capital Management's Anbio Biotechnology position peaked at $960K in Q3 2025.
  • 8 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.